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Women born after pre-eclamptic pregnancies have been reported to be at reduced risk of breast cancer as adults, because of
reduced intrauterine oestrogen inﬂuence on breast tissue; high levels of a-foetoprotein (a glycoprotein with anti-oestrogenic
properties), however, could also be important. In severe pre-eclampsia, placental function and foetal growth are reduced, and
umbilical cord plasma levels of a-foetoprotein could reﬂect the underlying processes. Umbilical cord blood was collected in
12804 consecutive deliveries. Among 307 pregnancies with clinical pre-eclampsia, 66 singleton pregnancies were identiﬁed as
clinically severe, and 610 singleton pregnancies were selected as controls. Oestradiol and a-foetoprotein were measured from
umbilical plasma, and birth weight was standardized as the ratio between the observed and expected birth weight, adjusted
for differences in gestation length and offspring sex. Cord plasma levels of a-foetoprotein were signiﬁcantly higher in severe
pre-eclampsia than controls (P50.01) after adjustment for gestational age and birth weight. For oestradiol, there was no
difference in cord plasma levels between the severe pre-eclampsia group and controls, after adjustment for length of gestation
and birth weight. These results suggest that an anti-oestrogenic effect associated with pre-eclampsia may be mediated through
high levels of a-foetoprotein rather than low levels of oestradiol.
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The hypothesis that breast cancer may originate in utero implies
that intrauterine factors that lead to higher birth weight increase
the risk of breast cancer in female offspring (Trichopoulos,
1990; Anbazhagan and Gusterson, 1994). The evidence related
to birth weight is suggestive, but not conclusive (Potischman
and Troisi, 1999). Two large Swedish studies, however, have
shown that women born after pre-eclamptic pregnancies have a
risk reduction for breast cancer of more than 50% (Ekbom et
al, 1992, 1997). The authors attributed this effect to lower intrau-
terine oestrogen inﬂuence on foetal breast tissue in pre-eclampsia
(Ekbom et al, 1992, 1997). However, the results of two recent
studies indicate that an alternative interpretation may be relevant,
since a-foetoprotein (AFP), a glycoprotein produced by the foetal
liver and yolk sac, also has anti-oestrogenic properties (Speroff et
al, 1983). Thus, a prospective study in Denmark has shown that
high serum concentrations of maternal a-foetoprotein in preg-
nancy were related to lower risk of maternal breast cancer
during follow-up (Melbye et al, 2000). An inverse association
between third trimester levels of AFP and subsequent risk of
breast cancer has also been reported by an American study
(Richardson et al, 1998).
AFP enters the maternal circulation through the placenta and
reaches its peak concentrations at the beginning of the third trime-
ster (Speroff et al, 1983). In animal models, AFP can inhibit growth
of oestrogen dependent mammary carcinomas in vivo (Jacobson et
al, 1990; Bennett et al, 1998) and recently, it has been shown that
human AFP peptides may bind the oestrogen receptor and
suppress breast cancer cell growth (Vakharia and Mizejewski,
2000).
We have hypothesized that the anti-oestrogenic effect of pre-
eclampsia could be mediated through high intrauterine levels of
AFP, rather than low levels of oestradiol. We have further
considered that an effect of severe pre-eclampsia could be related
to reduced foetal growth (Ødega ˚rd et al, 2000; Roberts and
Cooper, 2001). In a nested case–control study of pre-eclampsia
in Norway, we have therefore compared oestradiol and AFP in
umbilical cord plasma between cases of severe pre-eclampsia
and control infants. We have also studied the relation between
these two hormones in umbilical cord blood and infant birth
weight.
MATERIALS AND METHODS
Umbilical cord blood samples were collected in a prospective study
of pregnancy outcome that took place from January 1993 to
December 1995 at Rogaland Central Hospital in Stavanger,
Norway. The maternity clinic at this hospital serves a region of
approximately 239000 inhabitants. Deliveries (12804) took place
during the study period. The Norwegian Medical Birth Registry
records information on all deliveries that take place in the country
(Lie et al, 1998), and we used this information to identify cases of
pre-eclampsia and to select appropriate controls, as previously
described (Ødega ˚rd et al, 2000).
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mately 1300 cases with clinical information indicating possible pre-
eclampsia or eclampsia. After verifying and supplementing this
information with details from the hospital records, we identiﬁed
307 singleton pregnant women with deﬁnite pre-eclampsia. We
used a previously described deﬁnition of pre-eclampsia in this
study (CLASP Collaborative Group, 1994). Brieﬂy, for pre-eclamp-
sia to be diagnosed, persistent diastolic blood pressure of at least
90 mmHg had to develop after 20 weeks of gestation, and diastolic
blood pressure had to increase by at least 25 mmHg. In addition,
proteinuria had to be present, and cut-off was deﬁned as
0.3 mg l
71 (semiquantitative dipstick 1+) in at least one urine
sample after 20 weeks of gestation without simultaneous urinary
infection.
Pre-eclampsia was classiﬁed as severe (n=66) if diastolic blood
pressure increased to at least 110 mmHg, along with proteinuria
3+ on dipstick, or at least 500 mg per 24 h. Cases with eclampsia
and suspected HELLP (haemolysis elevated liver enzymes, low
platelets) syndrome were regarded interchangeable with severe
pre-eclampsia. Cord plasma was analysed for all 66 cases of severe
pre-eclampsia.
For comparison, women without pre-eclampsia were selected
from the cohort of women who gave birth at Rogaland Central
Hospital, as previously described (Ødega ˚rd et al, 2000). Among
619 control women, cord blood was available for analysis from
609. Information on baseline data was obtained at the ﬁrst mater-
nal visit at around 12 weeks of pregnancy. All infant data were
compiled from hospital records.
Blood samples were collected after delivery from the placental
side of the umbilical cord in syringes containing heparin, and
chilled to 48C up to 60 h before being centrifuged at
3000 r.p.m. for 15 min. Plasma was stored at 7808C until
analysed.
Birth weight was standardised as the ratio between the
observed and expected birth weight, the latter being adjusted
for sex and gestational age at birth. We used standards of
expected birth weights derived from the results of weight curves
based on ultra-sonographic measurements in a large Scandina-
vian population (Marsal et al, 1996). Gestational age at birth
was calculated from routine ultrasonographic measurements at
18 weeks of gestation. Small-for-Gestational-Age (SGA) was
deﬁned as an observed birth weight two standard deviations or
more below the expected, which corresponds to a ratio lower
than 0.76, or to a birth weight reduction of approximately 840
g for a term infant.
We measured oestradiol and AFP using commercially available
ﬂuoroimmunoassays (Wallac Oy, Turku, Finland). Single samples
were analysed, and procedures suggested by the manufacturer were
followed. Oestradiol and AFP were detected in all plasma samples.
In both assays, the intra-assay coefﬁcients of variation at high and
low levels were always less than 9%.
Oestradiol and AFP had positively skewed distributions, and
we used Mann–Whitney U-test for comparisons between the
groups. Differences between proportions were assessed by chi-
square tests. The standardised birth weight was divided into four
categories: 50.76 corresponds to a strict deﬁnition of small for
gestational age (SGA), and 0.76–0.89 is a broad category of rela-
tively small infants. The category 0.90 to 1.09 includes infants
with appropriate weight for their gestation, and the category
41.09 includes large babies. For each level of birth weight, we
estimated values of oestradiol and AFP in the pre-eclampsia
group and in controls. In multiple linear regression analyses,
we assessed whether the contribution to AFP or oestradiol
differed between cases of severe pre-eclampsia and controls, after
adjustment for length of gestation, birth weight and offspring
sex. All statistical analyses were calculated using the Statistical
Package for the Social Sciences (SPSS), version 10.05 (SPSS,
Inc., Chicago, IL, USA).
RESULTS
Table 1 shows that in severe pre-eclampsia, mean maternal age was
26.2 vs 28.2 years among controls, whereas mean length of gesta-
tion was 251 and 280 days. In the pre-eclampsia group, 71%
were primipara against 36.4% among controls. Infant birth weight
was substantially lower after severe pre-eclampsia (mean: 2527 vs
3565 grams), as was infant length (mean: 45.2 vs 49.9 cm).
In Table 2, we describe the control population according to
categories of maternal factors and sex of the infant. We found
higher oestradiol (P50.03) in umbilical cord plasma in younger
women, but no difference in AFP by maternal age. In primipara,
cord plasma oestradiol was higher than in multiparae (P50.001),
and there was a consistent reduction in cord plasma oestradiol
(P for trend 50.001) with increasing parity (Figure 1). For AFP,
we found no association with parity. There were no associations
between pre-pregnancy weight and cord levels of oestradiol or
AFP, and oestradiol and AFP did not signiﬁcantly differ between
smokers and non-smokers. Offspring birth weight was higher
among multiparae than among primipara, it was positively asso-
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Table 1 Characteristics of pregnancies (mean and standard deviation
and percentages) with severe pre-eclampsia and control pregnancies
Severe pre-eclampsia Controls
(n=66) (n=610)
Maternal age (years) 26.2 (0.6) 28.2 (0.2)
Gestational age (days) 251.2 (3.3) 280.3 (0.5)
Primipara (%) 71.2 36.4
Smoking in pregnancy (%) 15.9 26.8
Infant birth weight (g) 2527 (109) 3565 (21)
Infant length (%) 45.2 (0.6) 49.9 (0.1)
Caesarean sections (%) 51.5 5.6
Table 2 Maternal age, parity, pre-pregnancy weight, smoking in preg-
nancy, and offspring sex, related to median cord plasma levels of a-foeto
protein (AFP), oestradiol, amd mean birth weight of the offspring in 610
pregnancies not complicated by pre-eclampsia
525 years 525 years
Maternal age (n=136) (n=474) P-value
a
AFP (U ml
71) 57 065 53 490 0.6
Oestradiol (U ml
71) 21.2 18.5 0.01
Offspring weight (g) 3553 3569 0.3
Primipara Multiparae
Maternal parity (n=219) (n=384)
AFP (U ml
71) 53 400 54 740 0.4
Oestradiol (U ml
71) 24.4 17.0 50.001
Offspring weight (g) 3474 3652 0.001
5 564 kg 5 564 kg
Maternal weight (n>=286) (n=281)
AFP (U ml
71) 52 400 536 4930 0.8
Oestradiol (U ml
71) 20.0 19.1 0.9
Offspring weight (g) 3470 3652 50.001
Maternal smoking Non-smoker Smoker
in pregnancy (n=416) (n=152)
AFP (U ml
71) 52 450 56 480 0.6
Oestradiol (U ml
71) 19.5 20.0 0.9
Offspring weight (g) 3608 3419 50.001
Female Male
Offspring sex (n=302) (n=307)
AFP (U ml
71) 49 845 58 360 0.03
Oestradiol (U ml
71) 19.5 19.5 40.9
Offspring weight (g) 3513 3617 0.01
aMann–Whitney U-tests.
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188 g lower (P50.001) if the mother reported smoking at the
beginning of pregnancy. Birth weight was 106 g higher (P=0.01)
in boys than girls. Oestradiol did not signiﬁcantly differ by sex
of the newborn, but AFP was higher in boys than in girls
(P50.02).
Table 3 shows that median levels of cord plasma AFP were
approximately three times higher in severe pre-eclampsia than in
controls (P50.001). In contrast, there was no difference in oestra-
diol levels between the groups. Across categories of standardised
birth weight (Table 4), AFP was fairly uniform for both groups,
but at each level of birth weight, the absolute value of AFP was
approximately twice as high in the pre-eclampsia group as in
controls. Adjustment for length of gestation (in days) attenuated
the positive association between severe pre-eclampsia and AFP
(Table 5), but it remained statistically signiﬁcant (P=0.01). For
oestradiol (Table 6), the pre-eclampsia group had slightly but
not signiﬁcantly higher cord levels than the corresponding controls
at each level of birth weight, and further adjustment for gestational
age did not substantially change this result (data not shown).
DISCUSSION
Severe pre-eclampsia is characterised by abnormally shallow decid-
ual invasion by the trophoblast, placental hypoxia, and reduced
uteroplacental blood ﬂow (Roberts and Cooper, 2001). We found
that umbilical cord plasma AFP was substantially higher in severe
pre-eclampsia compared to controls, whereas cord plasma oestra-
diol did not differ between the groups. Neither AFP nor
oestradiol varied systematically with birth weight, but at each level
of birth weight, AFP was consistently and signiﬁcantly higher in
severe pre-eclampsia than in controls.
To our knowledge, no previous study has used umbilical
measurements of AFP and oestradiol to examine the association
between pre-eclampsia and birth weight. Our study was performed
within a population of nearly 13000 consecutive births (Ødega ˚rd et
al, 2000) for whom umbilical cord plasma was collected. The large
number of pregnancies and a strict clinical deﬁnition of pre-
eclampsia (CLASP Collaborative Group, 1994) allowed us to reli-
ably distinguish between mild and severe disease. We have also
beneﬁted from the results of a longitudinal study of Scandinavian
pregnancies (Marsal et al, 1996). By using repeated ultrasono-
graphic scans, the objective of that study was to establish
standards for foetal growth. Expected birth weights were derived
from these standards, and dividing observed birth weight by the
expected yielded standardised estimates for birth weight adjusted
for gestational age at birth and offspring sex.
The results in the control population (Table 2) were in line with
previous research in that lower birth weight was related to primi-
parity, maternal smoking, and to the newborn being of the female
sex. This supports the validity of the novel results of our investiga-
tion. We found substantially higher cord levels of AFP in boys than
girls, but no sex difference for oestradiol. Moreover, we found that
cord levels of oestradiol were inversely related to maternal age and
parity. This has been demonstrated previously in maternal blood
(Panagiotopoulou et al, 1990), and our results show a similar rela-
tion for oestradiol measured in cord blood.
In uncomplicated pregnancies, a-foetoprotein reaches its maxi-
mum at the beginning of the third trimester, and drops
thereafter towards term (Speroff et al, 1983). Cases of severe pre-
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Table 3 Median cord plasma levels of a-foeto protein (AFP) and
oestradiol, by pre-eclampsia status
Severe pre-eclampsia Controls
nn P -value
a
AFP (U ml
71)
a 65 184 970 609 54 060 50.001
Oestadiol
a (U ml
71) 66 23.6 610 19.5 0.9
aMann–Whitney U-tests.
Table 4 Median values of umbilical cord plasma a-foeto protein (AFP),
by levels of standardised birth weight
Servere
pre-eclampsia Controls
Standardised
(n=66) (n=610)
birth weight n AFP n AFP P-value
a
50.76 11 249 000 16 67 265 0.005
0.76–0.89 24 97 705 106 52 570 0.001
0.90–1.09 24 104 635 368 53 160 0.001
51.10 6 106 575 119 55 290 0.3
aMann–Whitney U-tests.
Table 5 Pre-eclampsia status, length of gestation, birth weight and
offspring sex as determinants of a-foetoprotein in multiple linear re-
gression analysis
Standardized coefﬁcent P-value
Pre-eclampsia vs controls 0.085 0.011
Gestation (days) 70.668 0.0001
Birth weight 70.072 0.081
Offspring sex (male) 0.097 0.001
Table 6 Median values of umbilical cord plasma oestradiol (U ml
71), by
levels of standardised birth weight
Severe
pre-eclampsia Controls
Standardised
(n=66) (n=609)
birth weight n Oestradiol n Oestradiol P-value
a
50.76 12 10.1 (17.7) 16 20.7 (21.1) 0.06
0.76–0.89 24 24.5 (26.4) 106 20.4 (16.0) 0.4
0.90–1.09 24 23.1 (29.8) 369 19.8 (16.4) 0.9
51.10 6 25.7 (17.5) 119 17.5 (14.3) 0.09
aMann–Whitney U-tests.
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British Journal of Cancer (2002) 86(5), 728–731 ã 2002 Cancer Research UKeclampsia typically require that births will be therapeutically
induced up to several weeks before term. Thus, collection of cord
blood may coincide with a period in gestation when AFP levels
would normally be higher than at term. Our results conﬁrm that
the association between severe pre-eclampsia and AFP was
confounded by differences in gestational age. By taking these differ-
ences into account, the association was substantially attenuated, but
remained statistically signiﬁcant.
Recent studies have found that women who were born after pre-
eclamptic pregnancies have a reduced risk of breast cancer in adult
life (Ekbom et al, 1992, 1997; Sanderson et al, 1996). Several
studies have also suggested that low birth weight may be associated
with reduced breast cancer risk (Ekbom et al, 1992; Michels et al,
1996; Stavola et al, 2000). Since severe pre-eclampsia clearly
reduces birth weight (Ødega ˚rd et al, 2000), one could speculate
that the risk reduction linked to pre-eclampsia is mediated by
restricted foetal growth. However, we found higher cord levels of
AFP in the severe pre-eclampsia group than in controls, even after
adjustment for birth weight and length of gestation. This ﬁnding
may reinforce recent experimental evidence that AFP may be a
factor with breast cancer inhibiting potential (Bennett et al, 1998,
Vakharia and Mizejewski, 2000). In adulthood, two studies have
recently related maternal blood levels of AFP during the second
or third trimester among pregnant women to these women’s subse-
quent risk of breast cancer (Richardson et al, 1998; Melbye et al,
2000). Both studies found that high pregnancy levels of AFP were
associated with lower maternal breast cancer risk, and the authors
attributed their ﬁndings to an anti-oestrogenic effect of AFP. Our
ﬁndings may be important because they indicate that elevated
AFP levels are associated with reduced breast cancer risk, not only
among the pregnant women, but also among their female offspring.
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